Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 27

Sort by

Sort Order Select

Journal Articles

Progression-Free Survival but Not Overall Survival Is Superior in Relapsed/Refractory Large B-Cell Lymphomas Treated with Axicabtagene Ciloleucel Compared to Tisagenlecleucel: Results of the CART-SIE Real Life Italian Study

Blood (2023) 142 (Supplement 1): 2118.

https://doi.org/10.1182/blood-2023-189300

Published: 2023

Journal Articles

Evaluating the Performance of Large Language Models in Hematopoietic Stem Cell Transplantation Decision Making

Ivan Civettini, Arianna Zappaterra, Daniele Ramazzotti, Bianca Maria Granelli, Giovanni Rindone, Andrea Aroldi, Stefano Bonfanti, Federica Colombo, Marilena Fedele, Giovanni Grillo, Matteo Parma, Paola Perfetti, Elisabetta Terruzzi, Carlo Gambacorti-Passerini, Fabrizio Cavalca

Blood (2023) 142 (Supplement 1): 3726.

https://doi.org/10.1182/blood-2023-185854

Published: 2023

Journal Articles

Positron Emission Tomography Evaluation in Relapsed/Refractory B-Cell Lymphoma Patients Treated with Anti-19 Chimeric Antigen Receptor (CAR) T-Cells in the CART-SIE Observational Study

Blood (2023) 142 (Supplement 1): 3517.

https://doi.org/10.1182/blood-2023-184614

Published: 2023

Journal Articles

Multiparametric Flow Cytometry-MRD Assay: Lesson from Phase II Trail REL AML 001

Blood (2023) 142 (Supplement 1): 5997.

https://doi.org/10.1182/blood-2023-185555

Published: 2023

Journal Articles

Evolutionary Portrait of Adult Core-Binding Factor Leukemia Patients Treated with a Continuation Therapy with Midostaurin: Preliminary Results

Blood (2022) 140 (Supplement 1): 9054–9056.

https://doi.org/10.1182/blood-2022-160024

Published: 2022

Journal Articles

Gimema ALL2418: Interim Analysis of a Phase Iia Study of Feasibility and Effectiveness of Inotuzumab Ozogamicin in Adult Patients with B-Cell Acute Lymphoblastic Leukemia with Positive Minimal Residual Disease before Any Hematopoietic Stem Cell Transplantation

Blood (2022) 140 (Supplement 1): 6119–6121.

https://doi.org/10.1182/blood-2022-157937

Published: 2022

Journal Articles

Overall Survival Improvement Following ALLO-SCT in Patients Older THAN 60 YEARS: A Gruppo Italiano Trapianto DI Midollo Osseo (GITMO) Registry Study

Michele Malagola, Nicola Polverelli, Massimo Martino, Vicky Rubini, Maria Teresa Lupo Stanghellini, Francesca Patriarca, Renato Fanin, Benedetto Bruno, Luisa Giaccone, Danilo Giuseppe Faraci, Giovanni Grillo, Stefania Bramanti, Luca Castagna, Paolo Bernasconi, Anna Amelia Colombo, Marco De Gobbi, Paolo Nicoli, Annalisa Natale, Stella Santarone, Elisabetta Terruzzi, Attilio Olivieri, Ilaria Scortechini, Patrizia Chiusolo, Elisabetta Metafuni, Angelo Michele Carella, Emanuela Merla, Marco Casini, Irene M Cavattoni, Mario Arpinati, Chiara Nozzoli, Ilaria Cutini, Patrizio Mazza, Annamaria Mazzone, Simona Bassi, Francesco Onida, Giorgia Saporiti, Filippo Antonio Canale, Adriana Vacca, Eugenia Piras, Piero Galieni, Sadia Falcioni, Mario Luppi, Giulia Debbia, Anna Paola Iori, Ursula La Rocca, Vincenzo Pavone, Anna Mele, Cristina Skert, Francesca Carobolante, Paola Carluccio, Carlo Borghero, Francesca Elice, Anna Proia, Fulvia Fanelli, Carmine Selleri, Nicoletta Sacchi, Sonia Mammoliti, Elena Oldani, Fabio Ciceri, Francesca Bonifazi, Domenico Russo

Blood (2021) 138 (Supplement 1): 1786.

https://doi.org/10.1182/blood-2021-145970

Published: 2021

Journal Articles

Enasidenib, an Oral Therapy in Mutant IDH2 Relapsed/Refractory Acute Myeloid Leukemia: A Real-Life Single Center Experience

Marta Riva, Lorenzo Rizzo, MD, Valentina Mancini, MD, Rosa Greco, MD, Giambattista Bertani, MD, Elisa Zucchetti, MD, Elisa Diral, MD, Michele Nichelatti, PhD, Silvio Marco Veronese, Giovanni Grillo, MD, Roberto Cairoli

Blood (2020) 136 (Supplement 1): 20–21.

https://doi.org/10.1182/blood-2020-141987

Published: 2020

Journal Articles

Safety Analysis of Ruxolitinib (RUX) Vs Best Available Therapy (BAT) in Patients (pts) with Steroid-Refractory (SR) Acute Graft-Vs-Host Disease (aGVHD) in the Randomized Phase 3 REACH2 Study

Blood (2020) 136 (Supplement 1): 40–42.

https://doi.org/10.1182/blood-2020-137603

Published: 2020

Journal Articles

Use of Post-Transplant Cyclophosphamide in One-Antigen Mismatched Unrelated Donor Transplantation Results in Similar Transplant Outcomes Than Haploidentical Hransplantation: A Retrospective Study on Behalf of the Acute Leukemia Working Party of the EBMT

Blood (2020) 136 (Supplement 1): 26–27.

https://doi.org/10.1182/blood-2020-137099

Published: 2020

Journal Articles

Prospective Evaluation of a Continuation Therapy with Midostaurin in Adult Patients with Core-Binding Factor Leukemia and Integrated Genetic Analysis: A Multi Center Phase II Study. Preliminary Results

Blood (2020) 136 (Supplement 1): 37–38.

https://doi.org/10.1182/blood-2020-137092

Published: 2020

Journal Articles

Biomarker Analysis in Patients (pts) with Steroid-Refractory Acute Graft-Vs-Host Disease (aGVHD) Treated with Ruxolitinib (RUX) or Best Available Therapy (BAT) in the Randomized, Phase 3 REACH2 Study

Blood (2020) 136 (Supplement 1): 26–27.

https://doi.org/10.1182/blood-2020-140403

Published: 2020

Journal Articles

Mapping the Road of Gvhd and GVT: A Longitudinal Study of Immune-Transcriptome Signatures As Novel Approach to Solve Post-Allogeneic Hematopoietic Cell Transplantation Dilemmas

Merav Bar, MD, Alice Woo, Mohammed Toufiq, Sabri Boughorbel, Darawan Rinchai, Mohammed Elanbari, Valentina Mattei, Rebecca Mathew, Irene Cavattoni, MD, Sabine Forer, Marco Zecca, Patrizia Comoli, Giovanni Grillo, MD, Catherine Cole, Chiara Cugno, MD, Sara Tomei, PhD, Damien Chaussabel, Sara Deola

Blood (2019) 134 (Supplement_1): 4550.

https://doi.org/10.1182/blood-2019-122884

Published: 2019

Journal Articles

Targeting WNT10B-Driven Signalling through Induction of FZD6 By Porcupine Inhibition in T Cell Acute Lymphoblastic Leukemia

Adriana Cassaro, PhD, Francesca Lazzaroni, Dr, Giovanni Grillo, MD, Gianluigi Reda, MD, Roberto Cairoli, MD, Alessandro Beghini

Blood (2019) 134 (Supplement_1): 3956.

https://doi.org/10.1182/blood-2019-124871

Published: 2019

Journal Articles

Administration of Plerixafor in Poor Mobilizers Allows Mobilization of Haematopoietic Progenitors: Clonogenic Potential and Engraftment Analysis

Laura Pezzetti, MSc, Giambattista Bertani, MD, Liliana Intropido, MSc, Tiziana Lamacchia, MSc, Mariateresa Pugliano, MD, Elisabetta Bice Volpato, MD, Elisa Zucchetti, MD, Giovanni Grillo, MD, Roberto Cairoli, MD

Blood (2019) 134 (Supplement_1): 5633.

https://doi.org/10.1182/blood-2019-125055

Published: 2019

Journal Articles

Targeted Therapy in FLT3-ITD Positive Myeloid Sarcoma: Proof of Principle

Giovanni Grillo, MD, Elisa Zucchetti, MD, Barbara Forno, MD, Ivana Lotesoriere, MD, Elena Inzoli, MD, Roberto Cairoli, MD

Blood (2017) 130 (Supplement 1): 5061.

https://doi.org/10.1182/blood.V130.Suppl_1.5061.5061

Published: 2017

Journal Articles

Retrospective Monocentric Study on Acute Myeloid Leukemias with Complex Karyotype: Clinical Outcomes and Cytogenetic Features

Giovanni Grillo, MD, Ivana Lotesoriere, MD, Elisa Zucchetti, MD, Valentina Mancini, MD, Barbara Forno, MD, Giambattista Bertani, MD, Elena Inzoli, MD, Silvia Soriani, Roberto Cairoli, MD

Blood (2017) 130 (Supplement 1): 5550.

https://doi.org/10.1182/blood.V130.Suppl_1.5550.5550

Published: 2017

Journal Articles

Impact of FLT3-ITD Mutations in Patients with Normal Karyotype Acute Myeloid Leukemia Undergoing Allogeneic Stem Cell Transplantation

Giovanni Grillo, MD, Elisa Zucchetti, MD, Elena Inzoli, MD, Valentina Mancini, MD, Barbara Forno, MD, Ivana Lotesoriere, MD, Giambattista Bertani, MD, Roberto Cairoli, MD

Blood (2017) 130 (Supplement 1): 5553.

https://doi.org/10.1182/blood.V130.Suppl_1.5553.5553

Published: 2017

Journal Articles

Role of Rituximab and Intensification with Autologous Stem Cell Transplantation in Primary Mediastinal B-Cell Lymphoma

Vittorio Ruggero Zilioli, Chiara Rusconi, Cristina Gabutti, Giovanni Grillo, Elisa Zucchetti, Erika Meli, Alessandro Monti, Antonino Greco, Marianna Caramella, Maddalena Mazzucchelli, Michele Nichelatti, Enrica Morra, MD

Blood (2012) 120 (21): 4851.

https://doi.org/10.1182/blood.V120.21.4851.4851

Published: 2012

Journal Articles

Reinforced Mini-BEAM Followed by Autologous Hematopoietic Stem Cell Infusion in Refractory Lymphoma: A Study of Feasibility and Efficacy

Chiara Rusconi, MD, Anna Maria Nosari, MD, Chiara Vanelli, MD, Vittorio Ruggero Zilioli, MD, Erika Ravelli, MD, Claudia Maria Basilico, MD, Livio Gargantini, MD, Laura Marbello, MD, Alfredo Molteni, MD, Giovanni Grillo, MD, Enrica Morra

Blood (2008) 112 (11): 4437.

https://doi.org/10.1182/blood.V112.11.4437.4437

Published: 2008

NARROW

Progression-Free Survival but Not Overall Survival Is Superior in Relapsed/Refractory Large B-Cell Lymphomas Treated with Axicabtagene Ciloleucel Compared to Tisagenlecleucel: Results of the CART-SIE Real Life Italian Study

Evaluating the Performance of Large Language Models in Hematopoietic Stem Cell Transplantation Decision Making

Positron Emission Tomography Evaluation in Relapsed/Refractory B-Cell Lymphoma Patients Treated with Anti-19 Chimeric Antigen Receptor (CAR) T-Cells in the CART-SIE Observational Study

Multiparametric Flow Cytometry-MRD Assay: Lesson from Phase II Trail REL AML 001

Evolutionary Portrait of Adult Core-Binding Factor Leukemia Patients Treated with a Continuation Therapy with Midostaurin: Preliminary Results

Gimema ALL2418: Interim Analysis of a Phase Iia Study of Feasibility and Effectiveness of Inotuzumab Ozogamicin in Adult Patients with B-Cell Acute Lymphoblastic Leukemia with Positive Minimal Residual Disease before Any Hematopoietic Stem Cell Transplantation

Overall Survival Improvement Following ALLO-SCT in Patients Older THAN 60 YEARS: A Gruppo Italiano Trapianto DI Midollo Osseo (GITMO) Registry Study

Enasidenib, an Oral Therapy in Mutant IDH2 Relapsed/Refractory Acute Myeloid Leukemia: A Real-Life Single Center Experience

Safety Analysis of Ruxolitinib (RUX) Vs Best Available Therapy (BAT) in Patients (pts) with Steroid-Refractory (SR) Acute Graft-Vs-Host Disease (aGVHD) in the Randomized Phase 3 REACH2 Study

Use of Post-Transplant Cyclophosphamide in One-Antigen Mismatched Unrelated Donor Transplantation Results in Similar Transplant Outcomes Than Haploidentical Hransplantation: A Retrospective Study on Behalf of the Acute Leukemia Working Party of the EBMT

Prospective Evaluation of a Continuation Therapy with Midostaurin in Adult Patients with Core-Binding Factor Leukemia and Integrated Genetic Analysis: A Multi Center Phase II Study. Preliminary Results

Biomarker Analysis in Patients (pts) with Steroid-Refractory Acute Graft-Vs-Host Disease (aGVHD) Treated with Ruxolitinib (RUX) or Best Available Therapy (BAT) in the Randomized, Phase 3 REACH2 Study

Mapping the Road of Gvhd and GVT: A Longitudinal Study of Immune-Transcriptome Signatures As Novel Approach to Solve Post-Allogeneic Hematopoietic Cell Transplantation Dilemmas

Targeting WNT10B-Driven Signalling through Induction of FZD6 By Porcupine Inhibition in T Cell Acute Lymphoblastic Leukemia

Administration of Plerixafor in Poor Mobilizers Allows Mobilization of Haematopoietic Progenitors: Clonogenic Potential and Engraftment Analysis

Targeted Therapy in FLT3-ITD Positive Myeloid Sarcoma: Proof of Principle

Retrospective Monocentric Study on Acute Myeloid Leukemias with Complex Karyotype: Clinical Outcomes and Cytogenetic Features

Impact of FLT3-ITD Mutations in Patients with Normal Karyotype Acute Myeloid Leukemia Undergoing Allogeneic Stem Cell Transplantation

Role of Rituximab and Intensification with Autologous Stem Cell Transplantation in Primary Mediastinal B-Cell Lymphoma

Reinforced Mini-BEAM Followed by Autologous Hematopoietic Stem Cell Infusion in Refractory Lymphoma: A Study of Feasibility and Efficacy

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only